RxDoctor Payments Data

Michael Zumer

Medical · Duncansville, PANPI 1144492786

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $21,884 of the $27,803 with a category attached, or 78.7%. 29 manufacturers reported payments, led by AbbVie at 25.3% of the total. Among medical clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$27,803in general payments, 2019–2025

Across 1,606 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • Amgen$7K
  • Pfizer$3K
  • Johnson & Johnson$3K
  • UCB, Inc.$1K
  • AstraZeneca$1K
  • plus $6K from 23 others

What the payments were for

  • Consulting fees$1000%
  • Speaking & faculty fees$5,43420%
  • Travel & lodging$380%
  • Food & beverage$21,88479%
  • Education$3471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,803 in reported general payments places this provider in the 95th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept63$590,308
Humira(Cf) PenAdalimumab68$571,897
RinvoqUpadacitinib70$510,286
Xeljanz XrTofacitinib Citrate29$179,340
OtezlaApremilast30$145,495
KevzaraSarilumab19$126,012
Hydroxychloroquine Sulfate535$24,802
MethotrexateMethotrexate Sodium596$17,019
Leflunomide103$5,159
SavellaMilnacipran Hcl11$5,151
Duloxetine Hcl219$4,742
Celecoxib171$4,452
Cevimeline Hcl15$3,868
Methylprednisolone163$2,398
Gabapentin163$2,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Savella$7,029$515,43881 claims
AmgenOtezla$6,797$145,49530 claims
SanofiKevzara$662$126,01219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Duncansville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →